Надана інформація про лікарські засоби призначена виключно для ознайомлення і не є офертою, рекламою чи інструкцією щодо застосування. Продаж, доставка та призначення препаратів через сайт не здійснюються. З питань застосування препарату ви можете записатися на очний прийом або онлайн-консультацію до профільного спеціаліста нашої клініки.
INVOKANA (ITALY)
In 1 film-coated tablet of 100 mg, it contains:
active ingredient:
102.0 mg of canagliflozin hemihydrate, equivalent to 100.0 mg of canagliflozin.
active ingredient:
102.0 mg of canagliflozin hemihydrate, equivalent to 100.0 mg of canagliflozin.
127у.е.
Invokana (international name — canagliflozin) is a medication used for the treatment of type 2 diabetes. It belongs to the class of sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors).
MECHANISM OF ACTION
SGLT2 inhibitors block the reabsorption of glucose in the proximal renal tubules, leading to the excretion of excess glucose in the urine. This reduces blood glucose levels independently of insulin and may contribute to weight loss and lower blood pressure.
FORMS OF RELEASE
Tablets of 100 mg and 300 mg
Trade name: Invokana®
Manufacturer: Janssen Pharmaceuticals
INDICATIONS
Type 2 diabetes:
- As monotherapy in case of metformin intolerance
- As an add-on to other hypoglycemic agents, including insulin
- Reduction of cardiovascular death risk in adults with type 2 diabetes and established cardiovascular disease
- Slowing the progression of diabetic nephropathy
DOSAGE REGIMEN
Initial dose - 100 mg once in the morning, before the first meal...
CONTRAINDICATIONS
- Type 1 diabetes
- Diabetic ketoacidosis
- Severe renal impairment (eGFR < 30 ml/min/1.73m²)
- Pregnancy and lactation
LABORATORY MONITORING
- Blood glucose (glucometer, HbA1c)
- Renal function (eGFR before starting, then regularly)
- Ketones in case of malaise symptoms
EFFECTS
- Reduction of HbA1c by 0.5–1.0%
- Weight loss of 2–4 kg
- Moderate reduction in systolic blood pressure (up to 5 mmHg)
COMPARISON:
Invokana (canagliflozin) with other SGLT2 inhibitors:
- Jardiance (empagliflozin) and
- Forxiga (dapagliflozin) — focusing on the advantages of Invokana:
1. Antidiabetic action
All three drugs effectively lower blood glucose levels in type 2 diabetes, but:
Invokana shows a slightly more pronounced reduction in HbA1c when used at a dose of 300 mg (by ~1% or more), while Jardiance and Forxiga typically reduce HbA1c by 0.5–0.8%.
This makes Invokana preferable for patients with higher baseline glucose levels and insufficient control on other medications.
2. Weight and blood pressure control
All three drugs reduce weight and blood pressure through osmotic diuresis and calorie loss in urine.
Clinical data show that Invokana 300 mg provides greater weight loss (up to 4 kg) and more pronounced reduction in systolic pressure (up to 6–8 mmHg) compared to others.
3. Nephroprotection
All three drugs have proven positive effects on the kidneys in patients with diabetic nephropathy.
However, Invokana was the first to receive an official indication for slowing the progression of chronic kidney disease, including in patients without diabetes, based on the CREDENCE study.
This makes it preferable for patients with albuminuria and reduced GFR.
4. Cardiovascular protection
All drugs reduce the risk of cardiovascular death and hospitalization for heart failure.
However, Jardiance has better results in reducing all-cause mortality in patients with established cardiovascular disease (EMPA-REG OUTCOME study).
Invokana, nevertheless, also demonstrated cardiovascular benefits (CANVAS), but not as pronounced.
5. Contraindications and safety
All drugs have similar risks: urinary tract infections, ketoacidosis, dehydration.
However, only Invokana is associated with an increased risk of lower limb amputations (especially in patients with neuropathy and vascular pathology).
This limits its use in patients with a high risk of foot complications.
6. Dosing flexibility
Invokana has two clearly separated doses: 100 mg and 300 mg, allowing for individualized therapy.
Jardiance and Forxiga have less flexible dosages: 10 mg and 25 mg (Jardiance) and 5 mg/10 mg (Forxiga).
Conclusion:
Advantages of Invokana:
- Stronger reduction in HbA1c at high dose
- Significant weight and blood pressure reduction
- Confirmed nephroprotection (including in non-diabetics)
- Option to choose between two therapeutic doses
Who is Invokana suitable for:
- Patients with poor glycemic control
- Patients with diabetic nephropathy
- Patients with obesity and hypertension
MECHANISM OF ACTION
SGLT2 inhibitors block the reabsorption of glucose in the proximal renal tubules, leading to the excretion of excess glucose in the urine. This reduces blood glucose levels independently of insulin and may contribute to weight loss and lower blood pressure.
FORMS OF RELEASE
Tablets of 100 mg and 300 mg
Trade name: Invokana®
Manufacturer: Janssen Pharmaceuticals
INDICATIONS
Type 2 diabetes:
- As monotherapy in case of metformin intolerance
- As an add-on to other hypoglycemic agents, including insulin
- Reduction of cardiovascular death risk in adults with type 2 diabetes and established cardiovascular disease
- Slowing the progression of diabetic nephropathy
DOSAGE REGIMEN
Initial dose - 100 mg once in the morning, before the first meal...
CONTRAINDICATIONS
- Type 1 diabetes
- Diabetic ketoacidosis
- Severe renal impairment (eGFR < 30 ml/min/1.73m²)
- Pregnancy and lactation
LABORATORY MONITORING
- Blood glucose (glucometer, HbA1c)
- Renal function (eGFR before starting, then regularly)
- Ketones in case of malaise symptoms
EFFECTS
- Reduction of HbA1c by 0.5–1.0%
- Weight loss of 2–4 kg
- Moderate reduction in systolic blood pressure (up to 5 mmHg)
COMPARISON:
Invokana (canagliflozin) with other SGLT2 inhibitors:
- Jardiance (empagliflozin) and
- Forxiga (dapagliflozin) — focusing on the advantages of Invokana:
1. Antidiabetic action
All three drugs effectively lower blood glucose levels in type 2 diabetes, but:
Invokana shows a slightly more pronounced reduction in HbA1c when used at a dose of 300 mg (by ~1% or more), while Jardiance and Forxiga typically reduce HbA1c by 0.5–0.8%.
This makes Invokana preferable for patients with higher baseline glucose levels and insufficient control on other medications.
2. Weight and blood pressure control
All three drugs reduce weight and blood pressure through osmotic diuresis and calorie loss in urine.
Clinical data show that Invokana 300 mg provides greater weight loss (up to 4 kg) and more pronounced reduction in systolic pressure (up to 6–8 mmHg) compared to others.
3. Nephroprotection
All three drugs have proven positive effects on the kidneys in patients with diabetic nephropathy.
However, Invokana was the first to receive an official indication for slowing the progression of chronic kidney disease, including in patients without diabetes, based on the CREDENCE study.
This makes it preferable for patients with albuminuria and reduced GFR.
4. Cardiovascular protection
All drugs reduce the risk of cardiovascular death and hospitalization for heart failure.
However, Jardiance has better results in reducing all-cause mortality in patients with established cardiovascular disease (EMPA-REG OUTCOME study).
Invokana, nevertheless, also demonstrated cardiovascular benefits (CANVAS), but not as pronounced.
5. Contraindications and safety
All drugs have similar risks: urinary tract infections, ketoacidosis, dehydration.
However, only Invokana is associated with an increased risk of lower limb amputations (especially in patients with neuropathy and vascular pathology).
This limits its use in patients with a high risk of foot complications.
6. Dosing flexibility
Invokana has two clearly separated doses: 100 mg and 300 mg, allowing for individualized therapy.
Jardiance and Forxiga have less flexible dosages: 10 mg and 25 mg (Jardiance) and 5 mg/10 mg (Forxiga).
Conclusion:
Advantages of Invokana:
- Stronger reduction in HbA1c at high dose
- Significant weight and blood pressure reduction
- Confirmed nephroprotection (including in non-diabetics)
- Option to choose between two therapeutic doses
Who is Invokana suitable for:
- Patients with poor glycemic control
- Patients with diabetic nephropathy
- Patients with obesity and hypertension
